WO2003013430A3 - Benzoquinone ansamycins - Google Patents
Benzoquinone ansamycins Download PDFInfo
- Publication number
- WO2003013430A3 WO2003013430A3 PCT/US2002/024891 US0224891W WO03013430A3 WO 2003013430 A3 WO2003013430 A3 WO 2003013430A3 US 0224891 W US0224891 W US 0224891W WO 03013430 A3 WO03013430 A3 WO 03013430A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- useful
- benzoquinone ansamycin
- cancer
- benzoquinone ansamycins
- benzoquinone
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
- C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002456175A CA2456175A1 (en) | 2001-08-06 | 2002-08-05 | Benzoquinone ansamycins |
EP02768436A EP1420747A4 (en) | 2001-08-06 | 2002-08-05 | Benzoquinone ansamycins |
AU2002330998A AU2002330998A1 (en) | 2001-08-06 | 2002-08-05 | Benzoquinone ansamycins |
JP2003518444A JP2005515164A (en) | 2001-08-06 | 2002-08-05 | Benzoquinone ansamycin |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31007901P | 2001-08-06 | 2001-08-06 | |
US60/310,079 | 2001-08-06 | ||
US38925502P | 2002-06-14 | 2002-06-14 | |
US60/389,255 | 2002-06-14 | ||
US39392902P | 2002-07-03 | 2002-07-03 | |
US60/393,929 | 2002-07-03 | ||
US39527502P | 2002-07-12 | 2002-07-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003013430A2 WO2003013430A2 (en) | 2003-02-20 |
WO2003013430A3 true WO2003013430A3 (en) | 2004-03-04 |
Family
ID=31982570
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/024891 WO2003013430A2 (en) | 2001-08-06 | 2002-08-05 | Benzoquinone ansamycins |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1420747A4 (en) |
AU (1) | AU2002330998A1 (en) |
WO (1) | WO2003013430A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9402831B2 (en) | 2011-11-14 | 2016-08-02 | Synta Pharmaceutical Corp. | Combination therapy of HSP90 inhibitors with BRAF inhibitors |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7189549B2 (en) * | 2002-06-14 | 2007-03-13 | Kosan Biosciences, Inc. | Recombinant polynucleotides encoding pro-geldanamycin producing polyketide synthase and accessory proteins, and uses thereof |
AU2004226350A1 (en) * | 2003-03-28 | 2004-10-14 | Kosan Biosciences, Inc. | Devices, methods, and compositions to prevent restenosis |
US20050020557A1 (en) * | 2003-05-30 | 2005-01-27 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors |
US20050020534A1 (en) * | 2003-05-30 | 2005-01-27 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites |
US6875863B1 (en) | 2003-11-12 | 2005-04-05 | Kosan Biosciences, Inc. | 11-O-methylgeldanamycin compounds |
JP4717003B2 (en) | 2003-11-12 | 2011-07-06 | コーサン バイオサイエンシーズ, インコーポレイテッド | 11-O-methylgeldanamycin compound |
US6855705B1 (en) | 2003-11-12 | 2005-02-15 | Kosan Biosciences, Inc. | 11-O-methylgeldanamycin compounds |
US6887993B1 (en) | 2003-11-12 | 2005-05-03 | Kosan Biosciences, Inc. | 11-O-methylgeldanamycin compounds |
US7282493B2 (en) | 2003-12-23 | 2007-10-16 | Infinity Pharmaceuticals, Inc. | Analogs of benzoquinone-containing ansamycins and methods of use thereof |
US20060019941A1 (en) * | 2003-12-23 | 2006-01-26 | Infinity Pharmaceuticals, Inc. | Analogs of benzoquinone-containing ansamycins and methods of use thereof |
US7259156B2 (en) * | 2004-05-20 | 2007-08-21 | Kosan Biosciences Incorporated | Geldanamycin compounds and method of use |
JP4954083B2 (en) | 2004-11-18 | 2012-06-13 | シンタ ファーマスーティカルズ コーポレイション | Triazole compounds that modulate HSP90 activity |
WO2007001049A1 (en) * | 2005-06-29 | 2007-01-04 | Kyowa Hakko Kogyo Co., Ltd. | Benzenoid ansamycin derivative |
JP5118039B2 (en) | 2005-08-18 | 2013-01-16 | シンタ ファーマシューティカルズ コーポレーション | Triazole compounds that modulate HSP90 activity |
CA2646316C (en) | 2006-03-15 | 2016-05-24 | Theralogics, Inc. | Methods of treating muscular wasting diseases using nf-kb activation inhibitors |
WO2007113268A1 (en) * | 2006-03-31 | 2007-10-11 | Biotica Technology Ltd. | 4, 5-dihydromacbecin derivatives and their use in the treatment of cancer or b-cell malignancies. |
GB0606542D0 (en) * | 2006-03-31 | 2006-05-10 | Biotica Tech Ltd | Novel compounds and methods for their production |
EP2073807A1 (en) | 2006-10-12 | 2009-07-01 | Astex Therapeutics Limited | Pharmaceutical combinations |
WO2008044041A1 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
PE20081506A1 (en) | 2006-12-12 | 2008-12-09 | Infinity Discovery Inc | ANSAMYCIN FORMULATIONS |
WO2009036092A2 (en) | 2007-09-10 | 2009-03-19 | University Of Massachusetts | Mitochondria-targeted anti-tumor agents |
CN101220068B (en) * | 2008-01-18 | 2012-06-13 | 中国医学科学院医药生物技术研究所 | A set of geldanamycin derivant and method for preparing the same |
ES2347619B1 (en) * | 2008-05-13 | 2011-09-15 | Consejo Superior De Investigaciones Cientificas (Csic) (50%) | PROCEDURE TO DESIGN AN ANTITUMORAL INDIVIDUAL THERAPY BASED ON THE DETECTION OF HSP90 PROTEIN LEVELS, THE USE OF HSP90 PROTEIN INHIBITORS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS, THE COMPOSITIONS AS OBTAINED AND THEIR APPLICATIONS. |
EP2348845A4 (en) | 2008-10-15 | 2013-01-23 | Infinity Pharmaceuticals Inc | Ansamycin hydroquinone compositions |
EP2560640A1 (en) | 2010-04-19 | 2013-02-27 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor |
CA2853806C (en) | 2011-11-02 | 2020-07-14 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with platinum-containing agents |
WO2013067162A1 (en) | 2011-11-02 | 2013-05-10 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
CN112679374A (en) * | 2021-01-12 | 2021-04-20 | 湖南复瑞生物医药技术有限责任公司 | Preparation method of 2-fluoro-6- (trifluoromethyl) benzamide |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4261989A (en) * | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS55111419A (en) * | 1979-02-20 | 1980-08-28 | Kaken Pharmaceut Co Ltd | Antitumorigenic agent |
CA2166320A1 (en) * | 1993-06-29 | 1995-01-12 | Randall James Gallaschun | Ansamycin derivatives as antioncogene and anticancer agents |
-
2002
- 2002-08-05 WO PCT/US2002/024891 patent/WO2003013430A2/en active Application Filing
- 2002-08-05 AU AU2002330998A patent/AU2002330998A1/en not_active Abandoned
- 2002-08-05 EP EP02768436A patent/EP1420747A4/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4261989A (en) * | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
Non-Patent Citations (2)
Title |
---|
SCHNUR ET AL.: "ervB-2 oncogene inhibition by geldanamycin derivatives: Synthesis, mechanism of action and structure-activity relationships", JOURNAL OF MEDICINAL CHEMISTRY, vol. 38, no. 19, 15 September 1995 (1995-09-15), pages 3813 - 3820, XP002193280 * |
See also references of EP1420747A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9402831B2 (en) | 2011-11-14 | 2016-08-02 | Synta Pharmaceutical Corp. | Combination therapy of HSP90 inhibitors with BRAF inhibitors |
Also Published As
Publication number | Publication date |
---|---|
EP1420747A4 (en) | 2010-06-02 |
AU2002330998A1 (en) | 2003-02-24 |
EP1420747A2 (en) | 2004-05-26 |
WO2003013430A2 (en) | 2003-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003013430A3 (en) | Benzoquinone ansamycins | |
WO2003030934A3 (en) | Cpg formulations and related methods | |
TW200630096A (en) | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity | |
WO2004028454A3 (en) | 1, 3, 5-triazines for treatment of viral diseases | |
WO2005120557A3 (en) | Inhibition of macrophage-stimulating protein receptor (ron) | |
CY1116463T1 (en) | Combination therapy for the therapeutic treatment of Protein Deficiency Disorders | |
MXPA04001523A (en) | Rapamycin dialdehydes. | |
WO2003096990A3 (en) | Protein cages for the delivery of medical imaging and therapy | |
WO2006037106A3 (en) | Carboxy-amido-triazoles for the localized treatment of ocular diseases | |
WO2003016467A3 (en) | Use of antibodies having high affinity for soluble ass to treat conditions and diseases related to ass | |
MXPA04001524A (en) | Rapamycin 29-enols. | |
BR0209147A (en) | Combination therapy using anti-egfr antibodies and antihormonal agents | |
WO2003047504A3 (en) | Prevention and treatment of androgen-deprivation induced osteoporosis | |
AU2003256755A1 (en) | Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations | |
DE60137337D1 (en) | PREVENTIVE AND THERAPEUTIC MONOCLONAL ANTIBODIES AGAINST VACCINIAVIRUSANTIGENE | |
WO2004009610A3 (en) | Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases | |
IL171974A0 (en) | Tetrahydrocarbazole derivatives and their pharmaceutical use | |
EA200500244A1 (en) | TETRAPROPILAMMONIA TETRATIOMOLYBDAT AND RELATED COMPOUNDS FOR ANTIANGIOGENIC THERAPY | |
WO2003106381A3 (en) | Human adam-10 inhibitors | |
HK1064950A1 (en) | Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s) | |
WO2010042489A3 (en) | Aminoquinoline derived heat shock protein 90 inhibitors, methods of preparing same, and methods for their use | |
WO2006019982A3 (en) | Pin1-modulating compounds and methods of use thereof | |
AP2004002995A0 (en) | Combination therapy for the treatment of cancer | |
MY137766A (en) | Exemestane as chemopreventing agent | |
YU24403A (en) | New retinoids for the treatment of emphysema |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG UZ VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2456175 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003518444 Country of ref document: JP |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002768436 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002768436 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |